Farmas USA

Jajaja, sí ya he caído en lo del tiempo y lo he cambiado. He puesto primer trimestre. Va, y añado lateral. :)

http://doodle.com/poll/r3mpaxczuhm3r28dwp8pztms/admin#table

CYTX

New Employee Incentive Plan (the "Incentive Plan")

The Board has reserved 1,000,000 shares of the Company's common stock for issuance pursuant to awards granted under the Incentive Plan, and the Incentive Plan will be administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the NASDAQ Listing Rules, awards under the Incentive Plan may only be made to an employee who has not previously been an employee or member of the Board or any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.

jajaja Bueno, si solo es Q1 pues bajista! jiji

Por cierto, veo en la encuesta cierta bipolaridad de framus. Tenemos un framus alcista (cuando está comprado) y otro bajista (el que espera para comprar)... jajaja

a ver esos futuros que USA se quiere ir al verde, IBEX y DAX verde

News GILD....

http://www.streetinsider.com/Corporate+News/Gilead+Sciences+%28GILD%29+Reports+Two+TAF+Phase+3s+Met+Primary+Objectives+in+Certain+HBV/11189552.html?si_client=intbro

http://www.streetinsider.com/Corporate+News/Gilead+Sciences+%28GILD%29+Receives+FDA+Priority+Review+for+Sofosbuvir+in+Chronic+HCV/11187110.html?si_client=intbro

Maxim Grop maintained Gilead Sciences (GILD) coverage with Buy and target $137

EDIT

IPO. Tecnología de edición genética CRISP. Cubierta por el Bastardo.

http://www.thestreet.com/story/13412168/1/editas-ipo-challenge-edit-investor-expectations-as-well-as-diseased-genes.html

Piper Jaffray maintained Alnylam Pharmaceuticals (ALNY) coverage with Overweight and target $184...

Ayer cerró en los 93.03$, lo que significa un potencial del 100%...

Un saludo

Yo he respondido lateral asumiendo que por mercado nos referimos al Nasdaq Biotech (reflejado en el IBB)... sospecho que habrá rallys alcistas a los que sucederán correcciones, pero veo el IBB a cierre del Q1-2016 más o menos por dónde andaba a finales de 2015.